Advertisement
Singapore markets closed

  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • Dow

    38,503.69
    +263.71 (+0.69%)
     

  • Nasdaq

    15,696.64
    +245.33 (+1.59%)
     

  • Bitcoin USD

    66,438.06
    +346.95 (+0.52%)
     

  • CMC Crypto 200

    1,434.48
    +10.38 (+0.73%)
     

  • FTSE 100

    8,088.68
    +43.87 (+0.55%)
     

  • Gold

    2,330.00
    -12.10 (-0.52%)
     

  • Crude Oil

    82.80
    -0.56 (-0.67%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     

  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Company News for May 12, 2020

Zacks Equity Research
·1-min read

  • Shares of Cellect Biotechnology Ltd. APOP surged 66.7% after the company announced the publication of an article in Bone Marrow Transplantation.

  • Shares of MyoKardia, Inc. MYOK soared 58.6% after the company announced that the primary and secondary endpoints for its Phase 3 EXPLORER clinical trials of Mavacamten were successful.

  • Shares of Amneal Pharmaceuticals, Inc. AMRX rose28.5% after the company’sQ1 earnings of $0.20 per share beat the Zacks Consensus Estimate of $0.08.

  • Shares of Bellerophon Therapeutics, Inc. BLPH gained19.2% after the company disclosed that the FDA has cleared initiation of Phase 3 study for INOpulse inhaled nitric oxide therapy to treat the novel coronavirus.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
MyoKardia Inc (MYOK) : Free Stock Analysis Report
 
Cellect Biotechnology Ltd (APOP) : Free Stock Analysis Report
 
AMNEAL PHARMACEUTICALS INC (AMRX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.